Pharmaceutical company Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals, announced on Saturday that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Imuldosa (DMB-3115), a biosimilar to Stelara (ustekinumab), marketed by Janssen Biotech, a Johnson & Johnson subsidiary.
Ustekinumab is a monoclonal antibody targeting cytokines involved in inflammatory and immune responses.
The CHMP recommendation bolsters Accord Healthcare's position in the autoimmune market, where it already has several specialty brands. This development aligns with Accord's strategy to expand its specialty portfolio. The company has 10 additional biosimilars in development, reinforcing its commitment to improving patient access to value-based medicines.
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
UCB and Biogen report positive Phase 3 results for dapirolizumab pegol in SLE
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Sareum Holdings secures patent allowance for SDC-1801 in China
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Carisma and Moderna expand collaboration
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Merck KGaA initiates Phase III trial for oral cladribine in gMG